Clin Oncol | Volume 1, Issue 1 | Research Article | Open Access

The Arg194Trp Polymorphism in the XRCC1 Gene Have No Associated With Lung Cancer Risk: A Meta-Analysis

Han Su1#, Yan Q1#, Qiang Hu2, Zhang M1, Sun J1, Na Li1, Huo L1, Zhiqin Gao1# and Mei-Hua Qu1#*


1Department of Pharmacology, Weifang Medical University, China
2Department of Pediatric Surgery, Weifang People’s Hospital, China
#Authors contributed equally in the paper

*Correspondance to: Mei-Hua Qu 

Fulltext PDF

Abstract

X-ray repair cross-complementing group 1(XRCC1) gene Arg194Trp polymorphism has been implicated in correlation with risk of lung cancer in some published studies, however, results of different studies have been inconsistent and some are totally different. In this study, we conducted a cumulative meta-analysis to get more comprehensive results of XRCC1 polymorphism of Arg194Trp and the risk of lung cancer from 27 case-control studies searching through the Pubmed, EBSCO and Embase database up to April 1, 2016. The meta-analysis was carried out by the Revman manager 5.3 Meta-Analysis software and the odds ratio (OR) with 95 % confidence interval (CI) was used to estimate the pooled effect. The results involving 9730 lung cancer patients and 13314 healthy controls revealed that XRCC1 Arg194Trp polymorphism was not associated with lung cancer risk [(OR= 0.90, 95 % CI=0.8-1.10) for ArgTrp vs. ArgArg; (OR=1.20, 95% CI=0.92-1.56) for TrpTrp vs. ArgArg; (OR=0.94, 95 % CI=0.83-1.07 for (TrpTrp+ArgTrp) vs. ArgArg]. The sensitivity and subgroups analysis showed that the results were robust and not affected by any single study with no publication bias. Our meta-analysis suggested that XRCC1 Arg194Trp polymorphism is not related with lung cancer.

Keywords:

X-ray repair cross-complementing group 1; XRCC1; Polymorphism; Lung cancer; Meta-analysis

Citation:

Han Su, Yan Q, Qiang Hu, Zhang M, Sun J, Na Li, et al. The Arg194Trp Polymorphism in the XRCC1 Gene Have No Associated With Lung Cancer Risk: A Meta-Analysis. Clin Oncol. 2016; 1: 1062.

Subscribe to Our Newsletter